Latest News

VALENCIA, Calif. — SetPoint Medical, a medical technology company dedicated to improving care for people living with chronic autoimmune diseases, today announced that it has initiated enrollment in the pilot clinical study evaluating Setpoint System® as a potential pro-remyelination therapy for adults living with relapsing-remitting multiple sclerosis (RRMS). The study received Investigational...
VALENCIA, Calif. — SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis (RRMS). Breakthrough...
Linköping, Sweden – A combination of only 11 proteins can predict long-term disability outcomes in multiple sclerosis (MS) for different individuals. The identified proteins could be used to tailor treatments to the individual based on the expected severity of the disease. The study, led by researchers at Linköping University in...
It’s a warm Tuesday afternoon and the Shalvey family is enjoying the sun out on their patio while their dogs, Sam and Jerry, run around the yard. Add in their white picket fence and the image is idyllic – but not uncommon for Bill and Lynne and their two daughters,...
SEATTLE, Washington — Shape Therapeutics, a leader in RNA editing-based gene therapy, today announced a partnership with the Rett Syndrome Research Trust (RSRT) to advance SHP-401, an investigational one-time gene therapy for Rett syndrome. Under the agreement, RSRT will fund translational studies to evaluate Shape’s RNAfix® guide RNA, designed to leverage...
Pittsburgh, Pennsylvania and Toronto, Ontario – Sharp Therapeutics Corp. (TSXV: SHRX) (“Sharp” or the “Company”), a preclinical-stage biotechnology company developing small molecule therapies to treat genetic diseases, today announced that it has engaged Rho, Inc. (“Rho”), a global contract research organization (CRO), to support Sharp’s preparation and planned submission of...
Matsumoto, Japan – Early detection and treatment of hereditary transthyretin-related amyloidosis via genetic counseling are crucial. Yet, not all at-risk individuals seek genetic counseling, and management for presymptomatic carriers remains unclear. To tackle these knowledge gaps, a research team from Japan conducted a retrospective study on over 200 people who...